caa a22 4500 477035213 CHVBK 20180405111303.0 cr unu---uuuuu 170330e19960701xx s 000 0 eng 10.1007/s002689900112 doi (NATIONALLICENCE)springer-10.1007/s002689900112 Epidermal Growth Factor Receptor Status in Hyperparathyroidism: Immunocytochemical and In Situ Hybridization Study [Elektronische Daten] [Gregory P. Sadler, John M. Morgan, Bharat Jasani, Anthony Douglas-Jones, Malcolm H. Wheeler] Abstract. The epidermal growth factor receptor (EGFr) family has been increasingly recognized as an important component in the control of normal cell proliferation and the pathogenesis of cancer. We have studied EGFr expression in 104 cases of hyperparathyroidism by immunocytochemistry (ICC) and by in situ hybridization (ISH). Using two different monoclonal antibodies, ICC for EGFr was performed on 66 cryostat sections and 38 wax-embedded parathyroid glands. ISH was performed on 49 of these glands using a cocktail of three anti-sense probes to EGFr mRNA and a nonspecific control probe to human HPV-18 virus. Breast and prostate tumors were employed as positive controls for both ICC and ISH. Controls demonstrated positive EGFr staining. None of the 104 parathyroid glands showed any ICC positivity. ISH displayed positive staining for EGFr mRNA in five of six carcinomas and eight of nine nonrenal hyperplastic glands. Only 3 of 15 adenomas and 3 of 19 renal hyperplastic glands showed positive staining. This difference was statistically significant between adenoma and carcinoma (: p < 0.05) and between adenoma and nonrenal hyperplasia ( p < 0.01) (Tukey's multiple comparison test). This study demonstrates that EGFr mRNA is present in parathyroid tumors. Expression in carcinoma and nonrenal hyperplasia is significantly different from adenoma and renal hyperplastic glands. In contrast, ICC failed to demonstrate EGFr protein expression. These findings suggest that either receptor numbers are too low to detect by ICC or there is a failure of mRNA translation. More studies are needed to establish whether the EGFr plays a role in the development of parathyroid cancer or hyperplasia. 1996 by the Société Internationale de Chir, ugie Sadler Gregory P. Department of Surgery, University Hospital of Wales, Heath Park, CF4 4XN Cardiff, U.K., GB aut Morgan John M. Department of Pathology, University Hospital of Wales, Heath Park, CF4 4XN Cardiff, U.K., GB aut Jasani Bharat Department of Pathology, University Hospital of Wales, Heath Park, CF4 4XN Cardiff, U.K., GB aut Douglas-Jones Anthony Department of Pathology, University Hospital of Wales, Heath Park, CF4 4XN Cardiff, U.K., GB aut Wheeler Malcolm H. Department of Surgery, University Hospital of Wales, Heath Park, CF4 4XN Cardiff, U.K., GB aut https://doi.org/10.1007/s002689900112 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002689900112 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sadler Gregory P. Department of Surgery, University Hospital of Wales, Heath Park, CF4 4XN Cardiff, U.K., GB aut NATIONALLICENCE 700 1- Morgan John M. Department of Pathology, University Hospital of Wales, Heath Park, CF4 4XN Cardiff, U.K., GB aut NATIONALLICENCE 700 1- Jasani Bharat Department of Pathology, University Hospital of Wales, Heath Park, CF4 4XN Cardiff, U.K., GB aut NATIONALLICENCE 700 1- Douglas-Jones Anthony Department of Pathology, University Hospital of Wales, Heath Park, CF4 4XN Cardiff, U.K., GB aut NATIONALLICENCE 700 1- Wheeler Malcolm H. Department of Surgery, University Hospital of Wales, Heath Park, CF4 4XN Cardiff, U.K., GB aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer